Tirzepatide

A dual GIP/GLP-1 receptor agonist with strong evidence for substantial weight loss and glycemic improvement in phase 3 trials.

Strong evidence FDA Approved GIP/GLP-1 Agonist

Written by WhatPeptide Editorial Team · Last updated 2026-03-17

Half-life

Approximately 5 days, enabling once-weekly dosing

Dosage range

2.5-15 mg once weekly (clinical literature context)

Administration

Subcutaneous injection

Research level

Strong

How Tirzepatide works

Tirzepatide co-agonizes GIP and GLP-1 receptors, combining incretin effects on insulin-glucagon balance with appetite suppression and delayed gastric emptying. The dual-receptor profile is associated with larger average weight reduction than older GLP-1 monotherapy in head-to-head studies. Effects remain dose-dependent and gastrointestinal side effects are common.

Also known as: Mounjaro, Zepbound, LY3298176

Clinical trial efficacy

[object Object]

Research relevance

Fat Loss

Strong research relevance 98

Anti-Aging & Longevity

Some relevance 35

Some relevance 25

Some relevance 20

Some relevance 20

Some relevance 20

Some relevance 20

Some relevance 20

Some relevance 20

Side effects & safety

Nausea Diarrhea Constipation Reduced appetite Pancreatitis (rare but serious) Thyroid C-cell tumors (boxed warning — rodent signal, human relevance uncertain) Gallbladder events (cholelithiasis, cholecystitis) Potential lean mass loss alongside fat loss

Contraindications

History of MTC/MEN2

Pregnancy

Pancreatitis history requires caution

Consult a healthcare provider before use if any of these apply to you.

Key studies

FAQ

What is Tirzepatide? +

A dual GIP/GLP-1 receptor agonist with strong evidence for substantial weight loss and glycemic improvement in phase 3 trials. Its mechanism of action is supported by robust clinical evidence.

What is Tirzepatide researched for? +

Tirzepatide has the strongest research relevance for Fat Loss, Anti-Aging & Longevity, Recovery & Healing. Evidence is supported by robust clinical evidence.

What are the side effects of Tirzepatide? +

Reported side effects include Nausea, Diarrhea, Constipation, Reduced appetite, Pancreatitis (rare but serious), Thyroid C-cell tumors (boxed warning — rodent signal, human relevance uncertain), Gallbladder events (cholelithiasis, cholecystitis), Potential lean mass loss alongside fat loss. Key contraindications: History of MTC/MEN2; Pregnancy; Pancreatitis history requires caution.

Is Tirzepatide FDA approved? +

Yes, Tirzepatide has FDA approval for specific indications. Always consult a healthcare provider for appropriate use.

How is Tirzepatide administered? +

Tirzepatide is typically administered via subcutaneous route. Researched dosage range: 2.5-15 mg once weekly (clinical literature context). Half-life: Approximately 5 days, enabling once-weekly dosing.

Explore similar peptides

Semaglutide

Strong evidence

GLP-1 Agonist

A long-acting GLP-1 receptor agonist with robust randomized evidence for glycemic control and body-weight reduction.

Retatrutide

Preliminary evidence

GLP-1/GIP/Glucagon Agonist

An investigational triple agonist (GLP-1/GIP/glucagon) with large early-stage weight-loss signals in phase 2 studies.

Tesamorelin

Strong evidence

GH Secretagogue

A stabilized GHRH analog approved for reduction of excess visceral fat in HIV-associated lipodystrophy.

CJC-1295

Moderate evidence

GH Secretagogue

A modified GHRH analog designed to prolong endogenous GH pulse support through albumin binding (DAC form). Originally placed on FDA Category 2 list (September 2023), then removed September 27, 2024 when the nominator withdrew. FDA still lists it under 'Other bulk drug substances that may present significant safety risks.' Regulatory status remains uncertain.